Format

Send to

Choose Destination
Alzheimers Res Ther. 2012 Jan 16;4(1):3. doi: 10.1186/alzrt101.

Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design.

Author information

1
Departments of Pharmacology and Neurology, Boston University School of Medicine, 715 Albany Street, Room R614, Boston, MA 02118-2526, USA. bwolozin@bu.edu.

Abstract

Recent trials of statins produced no benefit for subjects with Alzheimer's disease. These negative studies add to a growing list of negative clinical trials. These data point to a need for reevaluating the pathophysiology of late-onset Alzheimer's disease. Late-onset Alzheimer's disease might result from the cumulative effects of at least four different factors: β-amyloid accumulation, cardiovascular disease, aging and the associated loss of synaptic plasticity, and inflammation. Successful therapy of subjects with overt dementia might require approaches targeting all four pathophysiological domains.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center